

BRINGING THE
PROMISE OF CELL
THERAPY TO LIFE

Chimeric Therapeutics AGM
14 November 2023



DISCLAIMER

Certain statements contained in this presentation, including, without limitation, statements containing the words “believes,” “plans,” “expects,” “anticipates,” and words of similar import, constitute “forward-looking statements.” Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Chimeric (collectively, “Chimeric” or the “Company”) to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: the risk that our clinical trials will be delayed and not completed on a timely basis; the risk that the results from the clinical trials are not as favorable as we anticipate; the risk that our clinical trials will be more costly than anticipated; and the risk that applicable regulatory authorities may ask for additional data,

information or studies to be completed or provided prior to their approval of our products.

Given these uncertainties, undue reliance should not be placed on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements contained herein to reflect future events or developments except as required by law.

This presentation may not contain all the details and information necessary for you to make a decision or evaluation. Neither this presentation nor any of its contents may be used for any other purpose without the prior written consent of the Company.



Bringing the Promise of Cell Therapy to Life

2 CLINICAL TRIALS WITH POSITIVE PHASE 1 RESULTS

- Positive CHM 1101 Phase 1A data in recurrent brain cancer
- Positive CHM 0201 Phase 1A data in Acute Myeloid Leukemia and Advanced Colorectal Cancer
- Areas of high unmet medical need

ADVANCING CLINICAL DEVELOPMENT

- Innovative cell therapy portfolio with 3 novel technology platforms
- 4 ongoing clinical trials in solid tumours and blood cancers
- Multiple clinical catalysts in the next 12-18 months

EXPERIENCE AND EXPERTISE

- Team of experienced cell therapy experts
- Proven development and commercialization expertise
- Success in business development opportunities

CHIMERIC: A FOUNDATION FOR LONG TERM SUCCESS

3 NOVEL PLATFORM TECHNOLOGIES

CHM 1101
(CLTX CAR T)

2020

Best in class NK cell platform for
blood cancers and solid tumours



CHM 2101
(CDH17 CAR T)

2021

First in class CDH17 CAR T
for gastrointestinal cancers



CHM 0201
(CORE NK)

2022

Best in class NK cell platform for
blood cancers and solid tumours



CHM 1101: POSITIVE PHASE 1A CLINICAL DATA IN RECURRENT, LATE-STAGE BRAIN CANCER

DISEASE CONTROL RATE

55%

Disease Control Rate (DCR)
in heavily pretreated patients

Exceeding historical disease
control rates of 20-37%¹

SURVIVAL

~10 months

Median survival in patients
that achieved disease control

14+ months

Survival in two patients that
achieved disease control

~7 month survival expectation
after first recurrence²

SAFETY

Generally, well tolerated


- No Dose Limiting Toxicities
- No Cytokine Release Syndrome
- No Tumour Lysis Syndrome

1. Temozolomide DCR: = 37% Ref: DOI:10.1200/JCO.2009.26.5520 Journal of Clinical Oncology 28, no. 12 (April 20, 2010) 2051-2057; Lomustine DCR: 20% The Lancet Oncology: Volume 20, Issue 1, 1-164, 65
2. Gallego O. Nonsurgical treatment of recurrent glioblastoma. Curr Oncol. 2015 Aug;22(4):e273-81.

CHM 2101: FDA IND CLEARANCE

A FIRST-IN-CLASS 3RD GENERATION CAR T FOR GASTROINTESTINAL TUMOURS

- FDA clearance for Chimeric IND for a Phase 1 / 2 clinical program in Colorectal Cancer, Gastric Cancer and Neuroendocrine Tumours
- First-in-class CAR T cell therapy licenses from world renowned cell therapy center, the University of Pennsylvania after a decade of optimization
- Preclinical evidence published in Nature Cancer demonstrated complete eradication of tumor cells with no relapse in seven different types of cancer
- Clinical trial to be initiated in 2024 at leading US institutions



CHM 0201 for BLOOD CANCERS AND SOLID TUMOURS

ADVANCING NOVEL PHASE 1B CLINICAL COMBINATIONS

CHM 0201 Phase 1A

COMPLETE TO ENROLLMENT

Established Safety

Complete Response in Acute
Myeloid Leukemia

Demonstrated Persistence &
Expansions

CHM 0201 + VACTO Phase 1B

ONGOING ENROLLMENT

Initiated January 2023

Acute Myeloid Leukemia and
Colorectal Cancer

First Study to Investigate NK Cells +
Vactosertib

CHM 0201 + AZA/VEN Phase 1B


ENROLLMENT LATE 2023

FDA IND Clearance

Acute Myeloid Leukemia

First NK Combination Study in Front
Line AML

NEW CLINICAL TRIAL





VALUE PROPOSITION FOR INVESTORS

1.

ADVANCED, UNDervalUED PORTFOLIO

Chimeric's pipeline and portfolio are highly undervalued in relation to other cell therapy companies

2.

ADVANCING DEVELOPMENT TO VALUE REALIZATION

Chimeric's assets are entering Phase 1B, where big pharma M&A is now focused

3.

NAVIGATING THE CHALLENGES

Chimeric is responding to today's biotech environment with program prioritization, cash preservation and business development

1. ADVANCED, UNDERVALUED PORTFOLIO

Chimeric has an industry leading cell therapy portfolio with novel technology platforms in clinical stage development

CHM Asset	Tumour Type	Discovery/ Preclinical	Phase 1	Phase 2/ 3
CHM 1101 (CLTX CAR T)	Recurrent/ Progressive Glioblastoma	COH Phase 1A		
	Recurrent/ Progressive Glioblastoma	CHM Phase 1B		
	MMP2 Expressing Solid Tumours			
CHM 0201 (CORE NK)	Acute Myeloid Leukemia/ Colorectal Cancer	CWRU Ph. 1A IIT: COMPLETE		
	Hematological Malignancies / Solid Tumours	CWRU Ph. 1B + Vactosertib		
	Acute Myeloid Leukemia	MDACC Ph. 1B ADVENT AML		
0301	Hematological Malignancies			
1301	MMP2 Expressing Solid Tumours			
2301	CDH17 Expressing Solid Tumours			
CHM 2101 (CHM 2101)	Neuroendocrine Tumours	Ph. 1A Basket Trial		
	Gastric Cancer	Ph. 1A Basket Trial		
	Colorectal Cancer	Ph. 1A Basket Trial		

MDACC: MD Anderson Cancer Centre/ COH: City of Hope / CWRU: Case Western Reserve University

3

Novel technology platforms

2

Assets with positive clinical data

4

Ongoing clinical trials


2. VALUE REALIZATION OPPORTUNITY FOCUSES ON PHASE 1B/ 2

CHIMERIC IS ADVANCING DEVELOPMENT TO BIG PHARMA'S FOCUS

In today's market, big pharma M&A has shifted its focus from preclinical assets to assets that are clinically de-risked with Phase 1A/B data

Chimeric currently has 3 ongoing Phase 1B clinical trials.

As development advances to enhance M&A opportunity, funding requirements become more significant.



3. NAVIGATING THE CHALLENGES

To enable clinical advancement, Chimeric has responded to the challenges of today's market with program prioritization and cash preservation while creating value through business development





- ▶ **POSITIVE CLINICAL DATA in GBM and AML**
Two assets with positive Phase 1A clinical data
- ▶ **ADVANCING CLINICAL DEVELOPMENT**
Four ongoing clinical trials in solid tumours and blood cancers
- ▶ **NEAR TERM MILESTONES**
Multiple clinical catalysts in next 12-18 months
- ▶ **IMPACTFUL BUSINESS DEVELOPMENT**
Two collaborative clinical trials with limited CHM funding
- ▶ **INDUSTRY LEADING TEAM**
Experienced team with significant cell therapy development and commercialization expertise

CONTACT INFORMATION

Jennifer Chow

Chief Executive Officer and Managing Director

Chimeric Therapeutics Ltd

Cell: +1 908-723-8387

jchow@chimerictherapeutics.com

Paul A. Hopper

Executive Chairman

Chimeric Therapeutics Ltd

Cell: +61 406671515

paulhopper@lifescienceportfolio.com

